Logo image of TRMED.OL

THOR MEDICAL ASA (TRMED.OL) Stock Fundamental Analysis

OSL:TRMED - Euronext Oslo - NO0010597883 - Common Stock - Currency: NOK

2.525  -0.05 (-1.94%)

Fundamental Rating

2

Taking everything into account, TRMED scores 2 out of 10 in our fundamental rating. TRMED was compared to 71 industry peers in the Biotechnology industry. The financial health of TRMED is average, but there are quite some concerns on its profitability. TRMED does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TRMED had negative earnings in the past year.
In the past year TRMED has reported a negative cash flow from operations.
In the past 5 years TRMED always reported negative net income.
TRMED had a negative operating cash flow in each of the past 5 years.
TRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFTRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

With a decent Return On Assets value of -8.30%, TRMED is doing good in the industry, outperforming 63.38% of the companies in the same industry.
TRMED has a better Return On Equity (-10.22%) than 67.61% of its industry peers.
Industry RankSector Rank
ROA -8.3%
ROE -10.22%
ROIC N/A
ROA(3y)-146.91%
ROA(5y)-131.48%
ROE(3y)-270.57%
ROE(5y)-231.37%
ROIC(3y)N/A
ROIC(5y)N/A
TRMED.OL Yearly ROA, ROE, ROICTRMED.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

TRMED does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRMED.OL Yearly Profit, Operating, Gross MarginsTRMED.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, TRMED has more shares outstanding
The number of shares outstanding for TRMED has been increased compared to 5 years ago.
The debt/assets ratio for TRMED is higher compared to a year ago.
TRMED.OL Yearly Shares OutstandingTRMED.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
TRMED.OL Yearly Total Debt VS Total AssetsTRMED.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

TRMED has an Altman-Z score of 8.79. This indicates that TRMED is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.79, TRMED belongs to the best of the industry, outperforming 92.96% of the companies in the same industry.
TRMED has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
TRMED has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. TRMED outperforms 94.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.79
ROIC/WACCN/A
WACCN/A
TRMED.OL Yearly LT Debt VS Equity VS FCFTRMED.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 6.48 indicates that TRMED has no problem at all paying its short term obligations.
With an excellent Current ratio value of 6.48, TRMED belongs to the best of the industry, outperforming 87.32% of the companies in the same industry.
TRMED has a Quick Ratio of 6.48. This indicates that TRMED is financially healthy and has no problem in meeting its short term obligations.
TRMED has a better Quick ratio (6.48) than 87.32% of its industry peers.
Industry RankSector Rank
Current Ratio 6.48
Quick Ratio 6.48
TRMED.OL Yearly Current Assets VS Current LiabilitesTRMED.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.44% over the past year.
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.51%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRMED.OL Yearly Revenue VS EstimatesTRMED.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 200K 400K 600K
TRMED.OL Yearly EPS VS EstimatesTRMED.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRMED. In the last year negative earnings were reported.
Also next year TRMED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRMED.OL Price Earnings VS Forward Price EarningsTRMED.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRMED.OL Per share dataTRMED.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRMED!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THOR MEDICAL ASA

OSL:TRMED (5/6/2025, 7:00:00 PM)

2.525

-0.05 (-1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2024-02-28/amc
Earnings (Next)N/A N/A
Inst Owners0.78%
Inst Owner ChangeN/A
Ins Owners2.16%
Ins Owner ChangeN/A
Market Cap793.89M
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.05
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS0.83
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.3%
ROE -10.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-146.91%
ROA(5y)-131.48%
ROE(3y)-270.57%
ROE(5y)-231.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.48
Quick Ratio 6.48
Altman-Z 8.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.77%
EPS Next Y50.51%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y97.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y92.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.99%
OCF growth 3YN/A
OCF growth 5YN/A